Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics reports developments as a clinical-stage biotechnology company developing cancer immunotherapies. Company news centers on its proprietary Amphiphile, or AMP, technology, the ELI-002 program, and immunotherapy work for mKRAS-positive cancers including pancreatic ductal adenocarcinoma, colorectal cancer, lung cancer, and other KRAS-driven tumors.
Recurring updates also include clinical and regulatory disclosures, operating and financial results, healthcare-conference presentations, shareholder voting and governance matters, capital-structure actions, and Nasdaq inducement stock option grants under the company’s 2024 Inducement Incentive Award Plan.
Summary not available.
Summary not available.
Summary not available.